Daptomycin (CAS 103060-53-3) is a cyclic lipopeptide antibiotic used in the treatment of serious infections caused by Gram-positive organisms, including MRSA and Enterococcus species. It is administered intravenously and is indicated for complicated skin and skin structure infections, Staphylococcus aureus bacteremia and right-sided endocarditis.
The TCS GROUP product
Daptomycin 103060-53-3 | Lipopeptide Antibiotic API Supplier & Exporter
highlights the molecule’s origin from Streptomyces species and its role as a critical drug for multidrug-resistant Gram-positive pathogens. Daptomycin acts by binding to bacterial membranes in a calcium-dependent manner, causing rapid depolarisation, leakage of ions and subsequent inhibition of DNA, RNA and protein synthesis, culminating in cell death.
As a high-value injectable API, daptomycin fits squarely within the
Active Pharmaceutical Ingredient
catalogue of TCS INDUSTRIES LIMITED. It is often considered alongside other systemic anti-infectives in a hospital-care portfolio. For example, macrolide antibiotics such as
and broad-spectrum agents like Chloramphenicol 56-75-7 (also available from TCS GROUP) create opportunities for comprehensive anti-infective ranges covering both community and hospital indications.
While daptomycin is currently used exclusively via intravenous administration, manufacturers still need to handle critical issues such as:
- Sterile production and low endotoxin levels.
- Control of polymorphism and aggregation behaviour.
- Stability in lyophilised powders and reconstituted solutions.
TCS INDUSTRIES LIMITED provides detailed technical documentation, impurity profiles and stability guidance to help partners design robust formulations and packaging—commonly lyophilised vials reconstituted with compatible diluents.
Knowledge from oral dosage form development still adds value across the antibiotic portfolio. For instance, APIs formulated as tablets or capsules may utilise premium superdisintegrants such as
Croscarmellose Sodium – Superdisintegrant for Rapid Tablet Disintegration
to ensure rapid release, demonstrating the breadth of technologies available from TCS GROUP across routes of administration.
With Daptomycin 103060-53-3 from TCS INDUSTRIES LIMITED, manufacturers gain a reliable source of a critically important lipopeptide antibiotic, supported by strong quality systems and a broader portfolio that facilitates strategic positioning in the anti-infective market.